Media coverage about Pieris Pharmaceuticals (NASDAQ:PIRS) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pieris Pharmaceuticals earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.9759592733869 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern’s scoring:
Pieris Pharmaceuticals stock opened at $6.33 on Friday. The stock has a market capitalization of $340.90, a price-to-earnings ratio of -15.83 and a beta of 1.71. Pieris Pharmaceuticals has a twelve month low of $2.26 and a twelve month high of $9.75.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings results on Friday, March 9th. The biotechnology company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.21. The firm had revenue of $18.15 million for the quarter, compared to analysts’ expectations of $7.63 million. Pieris Pharmaceuticals had a negative net margin of 69.82% and a negative return on equity of 162.54%. equities research analysts anticipate that Pieris Pharmaceuticals will post -0.53 earnings per share for the current year.
PIRS has been the topic of a number of research analyst reports. HC Wainwright upped their target price on shares of Pieris Pharmaceuticals from $9.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, January 16th. BidaskClub cut shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 17th. William Blair initiated coverage on shares of Pieris Pharmaceuticals in a report on Wednesday, January 17th. They issued an “outperform” rating on the stock. ValuEngine raised shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Evercore ISI assumed coverage on shares of Pieris Pharmaceuticals in a report on Monday, March 19th. They issued an “outperform” rating and a $13.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $11.00.
In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 7,897 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $8.98, for a total value of $70,915.06. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.05% of the stock is owned by corporate insiders.
WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Pieris Pharmaceuticals (PIRS) Share Price” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-pieris-pharmaceuticals-pirs-share-price.html.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.